Intra-Cellular Therapies, Inc.
—- Market cap
- —
- Debt
- +$216.05M
- Cash
- −$306.95M
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ITCI stock price vs BJRI: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BJRI's multiple
Needs BJRI P/S.
Implied fair value · at ITCI's multiple
Needs ITCI P/S.
Metric by metric
Price unavailable
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ITCI FY 2024 (ended Dec 31, 2024) · BJRI FY 2025 (ended Dec 30, 2025). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Intra-Cellular Therapies, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
BJ’S RESTAURANTS, INC. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.19x
0.23x
Net debt / EBITDA
Leverage against operating earnings
1.23x
1.19x
Cash and equivalents
Liquid reserves on the balance sheet
$306.95M
$23.78M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
SUPERNUS PHARMACEUTICALS, INC.
ITCI vs SUPN
ACADIA PHARMACEUTICALS INC
ITCI vs ACAD
Vanda Pharmaceuticals Inc.
ITCI vs VNDA
Sage Therapeutics, Inc.
ITCI vs SAGE
Bloomin' Brands, Inc.
ITCI vs BLMN
Dine Brands Global, Inc.
ITCI vs DIN
Texas Roadhouse, Inc.
ITCI vs TXRH
CRACKER BARREL OLD COUNTRY STORE, INC
ITCI vs CBRL
$216.05M
$85.00M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.